Dr. John Lewis

Dr. John Lewis

Company: Oisin Biotechnologies

Job title: Chief Science Officer

Bio:

Dr. John Lewis is the Chief Science Officer of Oisin Biotechnologies and heads its cancer-fighting platform technology development and clinical research. Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta. He is an Associate Professor in the Department of Oncology and chairs the Alberta Prostate Cancer Research Initiative. Dr. Lewis has previously founded several biotechnology companies, including Entos Pharmaceuticals, which has developed the innovative lipid nanoparticle gene therapy platform that Oisin is utilizing for clinical development.

Seminars:

Chair’s Closing Remarks 4:45 pm

Read more

day: Day Two

Chair’s Opening Remarks 8:05 am

Read more

day: Day Two

Chair’s Closing Remarks 5:10 pm

Read more

day: Day One

A Novel Apoptotic Gene Therapy Approach for Systemic Senolysis 1:30 pm

Overviewing Oisin’s LNP Gene Therapy Platform for selective ablation of senescent cells Discussioning recent biodistribution and efficacy results in small and large animal models Updating on recent longevity data in animal models Overviewing clinical development plansRead more

day: Day One

Chair’s Opening Remarks 8:00 am

Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.